Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from QatarShow others and affiliations
2019 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 74, no 12, p. 3497-3504Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: To investigate the in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against clinical isolates of MDR Pseudomonas aeruginosa from Qatar, as well as the mechanisms of resistance.
METHODS: MDR P. aeruginosa isolated between October 2014 and September 2015 from all public hospitals in Qatar were included. The BD PhoenixTM system was used for identification and initial antimicrobial susceptibility testing, while Liofilchem MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for confirmation of ceftazidime/avibactam and ceftolozane/tazobactam susceptibility. Ten ceftazidime/avibactam- and/or ceftolozane/tazobactam-resistant isolates were randomly selected for WGS.
RESULTS: A total of 205 MDR P. aeruginosa isolates were included. Of these, 141 (68.8%) were susceptible to ceftazidime/avibactam, 129 (62.9%) were susceptible to ceftolozane/tazobactam, 121 (59.0%) were susceptible to both and 56 (27.3%) were susceptible to neither. Twenty (9.8%) isolates were susceptible to ceftazidime/avibactam but not to ceftolozane/tazobactam and only 8 (3.9%) were susceptible to ceftolozane/tazobactam but not to ceftazidime/avibactam. Less than 50% of XDR isolates were susceptible to ceftazidime/avibactam or ceftolozane/tazobactam. The 10 sequenced isolates belonged to six different STs and all produced AmpC and OXA enzymes; 5 (50%) produced ESBL and 4 (40%) produced VIM enzymes.
CONCLUSIONS: MDR P. aeruginosa susceptibility rates to ceftazidime/avibactam and ceftolozane/tazobactam were higher than those to all existing antipseudomonal agents, except colistin, but were less than 50% in extremely resistant isolates. Non-susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam was largely due to the production of ESBL and VIM enzymes. Ceftazidime/avibactam and ceftolozane/tazobactam are possible options for some patients with MDR P. aeruginosa in Qatar.
Place, publisher, year, edition, pages
Oxford University Press, 2019. Vol. 74, no 12, p. 3497-3504
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-78572DOI: 10.1093/jac/dkz379ISI: 000501732800012PubMedID: 31504587Scopus ID: 2-s2.0-85075093622OAI: oai:DiVA.org:oru-78572DiVA, id: diva2:1377648
Funder
Swedish Research Council Formas, 219-2014-837
Note
Funding Agencies:
Medical Research Centre at Hamad Medical Corporation, Doha, Qatar IRGC-01-51-033
United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Institute of Allergy & Infectious Diseases (NIAID) R01AI100560 R01AI063517 R01AI072219
Cleveland Department of Veterans Affairs from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development 1I01BX001974
Cleveland Department of Veterans Affairs from the Geriatric Research Education and Clinical Center VISN 10 1I01BX001974
2019-12-122019-12-122020-11-24Bibliographically approved
In thesis